54 results about "RSV Infections" patented technology

The invention discloses a nano antibody of pre-F protein of a targeted respiratory syncytial virus and application of the nano antibody. The nano antibody comprises a heavy chain variable region, and the heavy chain variable region comprises heavy chain complementary determining regions CDR1, CDR2 and CDR3. The nano antibody disclosed by the invention can be specifically combined with RSV, and has a good application prospect in the aspect of RSV infection related diseases.

The application belongs to the technical field of biological medicine, and particularly relates to a RSV pre-fusion F protein mutant and application thereof. The RSV pre-fusion F protein mutant has good stability, high expression and / or immunogenicity, and can be used for preparing a RSV antibody, preventing RSV infection, preventing and / or treating a disease caused by RSV infection, detecting the presence or content of the RSV antibody in a sample, diagnosing RSV infection, and diagnosing a disease caused by RSV infection.

The invention relates to an application of a PROTAC compound targeting M2-1 protein in preparation of an anti-RSV (Respiratory Syndrome Virus) drug, and belongs to the technical field of biological medicines. According to the invention, by constructing bifunctional micromolecules capable of simultaneously combining the M2-1 protein and CRBN E3 ubiquitin ligase, selective degradation of the M2-1 protein is realized, the limitation that the protein cannot be effectively targeted in the prior art is broken through, and a new technical approach is provided for solving the problems of single target spot, high drug resistance risk, lack of specific drugs and the like in RSV infection treatment; the method has obvious novelty and substantial progress.

The present invention relates to vaccination against respiratory syncytial virus (RSV), in particular to the use of a vaccine formulation comprising an RSV F fusion protein (RSV F protein) antigen and an adjuvant in methods of prevention of RSV infection and disease in older adults.

The application of OsFabF gene in resistance to rice stripe virus, the application relates to the technical field of rice disease resistance breeding. The application uses a CRISPR / Cas9 gene editing system to design sgRNA targeting a specific functional region of an endogenous OsFabF gene in rice, to precisely edit the region, thereby obtaining a mutant with a functionally deficient OsFabF. The editing preferably results in a frame shift mutation or a premature stop codon, to obtain a truncated OsFabF protein mutant. Experiments show that the rice mutant plant obtained in this way exhibits significantly enhanced resistance to RSV infection, reduced virus accumulation and reduced disease symptoms. The application provides an effective gene target and breeding material for cultivating new rice varieties resistant to rice stripe virus.

Provided are a fusion protein, and a nucleic acid molecule comprising a nucleotide sequence encoding the fusion protein. The present invention also relates to a vaccine comprising the fusion protein or the nucleic acid molecule. Furthermore, the present invention also relates to a method for preventing and / or treating RSV infections or diseases and / or symptoms caused by RSV infections by means of using the fusion protein, nucleic acid molecule and vaccine.

An immunogenic composition comprising recombinant peptides and proteins comprising respiratory syncytial virus (RSV) viral antigens and immunogens, such as RSVF protein peptides. The immunogenic composition comprises a secreted fusion protein, the secreted fusion protein comprises a soluble RSV virus antigen, and the soluble RSV virus antigen and a collagen C-terminal part are linked through in-frame fusion to form a disulfide bond linked trimeric fusion protein. The immunogenic compositions may be used to generate an immune response, for example, in the treatment or prevention of RSV infection. The immunogenic compositions may be used in vaccine compositions, for example as part of prophylactic and / or therapeutic vaccines. Also provided are methods of producing the recombinant peptides and proteins, prophylactic, therapeutic and / or diagnostic methods, and related kits.

The application belongs to the technical field of biological medicine, and particularly relates to a RSV pre-fusion F protein mutant and application thereof. The RSV pre-fusion F protein mutant has good stability, high expression and / or immunogenicity, and can be used for preparing a RSV antibody, preventing RSV infection, preventing and / or treating a disease caused by RSV infection, detecting the presence or content of the RSV antibody in a sample, diagnosing RSV infection, and diagnosing a disease caused by RSV infection.

The invention discloses an application of FAM20C protein or a coding gene thereof in preparation of an anti-RSV drug, and relates to the technical field of gene functions and application, and the FAM20C protein or the coding gene thereof is an action target of the drug; 1, and the amino acid sequence of the FAM20C protein is as shown in SEQ ID NO. 2. According to the invention, the relationship between the FAM20C gene / protein and RSV infection is determined, the FAM20C gene / protein can be used as a therapeutic target of RSV infection, the replication of RSV virus can be inhibited by knocking down the FAM20C gene, and the inhibitor FL-1607 of the FAM20C gene can be used for treating RSV infection. The invention provides an effective new way for the treatment of RSV (Respiratory Syndrome Virus) infection.

In order to further reduce the risk of respiratory syncytial virus in immunocompromised populations, novel mRNA vaccines for the prevention of RSV are provided that are superior in stability and significantly enhance humoral immunity after vaccination.SOLUTION: A respiratory syncytial virus (RSV) vaccine comprising RNA encoding an RSVF protein or mutant thereof, and methods of making the same. The vaccine can prevent RSV infection and its complications.SELECTED DRAWING: Figure 1

The invention relates to a nano antibody for detecting respiratory syncytial virus and application thereof. In particular to a nano antibody specifically combined with respiratory syncytial virus F glycoprotein, which comprises a CDR1 shown as SEQ ID NO: 3, a CDR2 shown as SEQ ID NO: 4 and a CDR3 shown as SEQ ID NO: 5. The nano antibody provided by the invention has the characteristics of strong specificity, high sensitivity and high stability, and has wide application prospects and important economic and social meanings in the research aspects of development of RSV infection detection reagents, targeted drug delivery, neutralizing antibody treatment and the like.

This invention discloses a monoclonal antibody against RSV NS2 protein and its applications, relating to the field of bioimmunotechnology. The monoclonal antibody comprises the following amino acid sequences: CDR-H1 (SEQ ID NO. 7), CDR-H2 (SEQ ID NO. 9), CDR-H3 (SEQ ID NO. 11), CDR-L1 (SEQ ID NO. 14), CDR-L2 (LVS), and CDR-L3 (SEQ ID NO. 17). This monoclonal antibody can specifically bind to the RSV NS2 protein and can be applied to various detection methods for RSV NS2 protein, providing an important research tool for studying RSV infection mechanisms and establishing related detection technologies.

The invention provides an anti-respiratory syncytial virus (RSV) monoclonal antibody preparation as well as a preparation method and application of the preparation. The preparation disclosed by the invention has osmotic pressure similar to physiological conditions, not only contains high-concentration antibodies and can provide a drug level with the highest therapeutic benefit, but also has good storage stability, and better antibody preparations and therapies are provided for prevention and treatment of RSV (Respiratory Syndrome Virus) infection.

The invention relates to the technical field of biomedicine, in particular to application of arachidonic acid ethanolamine as a respiratory syncytial virus infection biomarker. According to the application, after the change of metabolome in RSV infected host cells is studied, the content of arachidonic acid ethanolamine AEA is obviously increased, so that the arachidonic acid ethanolamine AEA can be used as a biomarker for early detection or evaluation of RSA infection, the specificity is high, a high-sensitivity diagnostic marker is provided for prevention and treatment of RSV infection, and targeted intervention of RSV prevention and treatment is expected to be promoted.

The present disclosure relates to compositions comprising RNA molecules encoding influenza-derived antigens, where the RNA may be formulated in lipid nanoparticles (LNPs), and the compositions further comprise a polypeptide antigen derived from respiratory syncytial virus (RSV) and / or an RNA molecule encoding an antigen derived from RSV, where the RSV RNA may be formulated in LNPs. The present disclosure further relates to the use of RNA molecules, RNA-LNPs, and compositions for the prevention of influenza and RSV infection-induced illnesses.

The present disclosure belongs to the technical field of mRNA vaccines, and particularly relates to a respiratory syncytial virus (RSV) vaccine, and a preparation method therefor and use thereof. The vaccine provided by the present disclosure comprises RNA encoding an RSV F protein or a variant thereof. The vaccine can prevent an RSV infection and complications thereof.

The application discloses a kind of based on CLDN1 protein's derivative peptide, fusion protein and its application, the derivative peptide includes the amino acid sequence as shown in SEQ ID NO:3, the amino acid sequence of the fusion protein is as shown in SEQ ID NO:2.The application finds that several derivative peptides containing CLDN1 protein extracellular loop EL1 peptide segment have significant inhibitory effect on various RNA and DNA envelope viruses.The fusion protein shows significant in vivo antiviral activity, can alleviate lung inflammation caused by RSV infection, and reduce viral nucleic acid level.Therefore, the derivative peptide and fusion protein based on CLDN1 protein designed in the application can be used for antiviral therapy or prophylactic drug research and development, and have wide application prospect.

Compositions and methods of inducing an immune response in a subject having RSV comprising administering a pharmaceutical composition comprising a prophylactic vaccine against RSV infection, wherein the vaccine comprises a live recombinant canine parainfluenza (CPI) vector backbone engineered to express a RSV F protein.

A conjugate compound comprising (i) a ligand of a protein targeting RSV or RSV-infected cells, (ii) one or more linkers, and (iii) two or more haptens; a pharmaceutical composition comprising the conjugate compound; and a method of delivering the pharmaceutical agent to RSV or RSV-infected cells for therapeutic purposes.

Provided are a method for inactivating respiratory syncytial virus (RSV) and stabilizing pre-F protein in RSV and inactivated RSV virus obtained thereby. Also provided are a vaccine comprising the inactivated RSV virus and a use of the vaccine in preventing or treating RSV infection or a disease related thereto.

This invention relates to the field of biotechnology, specifically to a monoclonal antibody against respiratory syncytial virus (RSV), its preparation method, and its applications. The RSV monoclonal antibody provided by this invention can recognize specific antigenic epitopes of the pre-F protein of RSV. Results from examples show that the monoclonal antibody has a strong affinity for the RSV F protein and exhibits high neutralizing efficacy against both RSV types A and B, thus preventing RSV infection. The drug for treating RSV provided by this invention contains a monoclonal antibody against RSV and provides good protection against RSV infection. The preparation method of the RSV monoclonal antibody provided by this invention is cost-effective and simple to operate.

The present application relates to a polypeptide membrane fusion inhibitor against RSV and its preparation method and use. The present application discloses a compound, a pharmaceutical salt thereof or a derivative thereof, a pharmaceutical composition containing the same, and a preparation product, and the use thereof in the preparation of a medicine for preventing and / or treating diseases caused by RSV or other paramyxoviridae viruses. The polypeptide of the present application shows significantly better anti-RSV activity and safety than the positive control polypeptide. Molecular interaction experiments show that the polypeptide acts on the NHR region of RSV F protein, inhibits the process of NHR forming a six-helix bundle with CHR in F protein, which is a key step of RSV infection, by forming an inactive six-helix structure with NHR or by destroying the structure of RSV NHR, thereby preventing the fusion of RSV virus with target cells.

To provide a pharmaceutical composition for maternal immunization.SOLUTION: The invention provides a pharmaceutical composition for maternal immunization, wherein the pharmaceutical composition comprises an RSVF protein and an adjuvant, wherein the pharmaceutical composition is administered to a pregnant female carrying a gestational infant, wherein the maternal immunization induces an immune response against at least one symptom associated with RSV lower respiratory tract infection (LRTI) in the infant after birth, wherein the pregnant female is at about 28 weeks to about 33 weeks of gestation, and wherein the RSVF protein comprises SEQ ID NO:

The present invention relates to an RSV pre-fusion F protein mutant and the use thereof. The RSV pre-fusion F protein mutant has a relatively good stability and a relatively high expression level and / or immunogenicity, and can be used for preparing RSV antibodies, preventing RSV infections, preventing and / or treating diseases caused by RSV infections, detecting the presence or amount of RSV antibodies in a sample, diagnosing RSV infections, and diagnosing diseases caused by RSV infections.

This disclosure relates to structurally-stabilized (e.g., stapled, e.g., hydrocarbon stapled) respiratory syncytial virus (RSV) peptides and variants thereof, and structurally-stabilized (e.g., stapled, e.g., hydrocarbon stapled) RSV peptides and variants thereof, conjugated with polyethylene glycol (PEG) and / or cholesterol (or a variant thereof, e.g., thiocholesterol), e.g., a PEG(n)-cholesterol or PEG(n)-thiocholesterol derivatization, and methods for using such structurally-stabilized peptides and conjugates in the prevention and treatment of an RSV infection in a subject (e.g., human).

The invention discloses a respiratory syncytial virus F protein antibody and application thereof. The invention provides a brand new antibody targeting respiratory syncytial virus (RSV) F protein for the field, and the antibody can be specifically combined with the RSV F protein and has good affinity and specificity. The invention lays a foundation for developing RSV F protein detection and / or auxiliary detection products in the field, and meanwhile, the invention is expected to provide more diagnostic tools and treatment strategies for diagnosis and / or treatment of RSV infection related diseases, and has wide clinical application prospects.

The invention provides an application of an anti-RSV antibody in preventing and treating RSV. The anti-RSV antibody can provide enough anti-RSV infection protection for infants entering the first RSV epidemic season.

This disclosure relates to RNA molecules encoding respiratory syncytial virus (RSV). This disclosure further relates to compositions comprising RNA molecules formulated in lipid nanoparticles (RNA-LNPs). This disclosure further relates to the use of RNA molecules, RNA-LNPs, and compositions for the treatment and / or prevention of RSV infection-induced acute respiratory tract diseases, including pneumonia and bronchitis.

This disclosure provides recombinant respiratory syncytial virus (RSV) antigens and methods for making and using them, including immunogenic compositions (e.g. vaccines) for the treatment and / or prevention of RSV infection.

The invention discloses application of a substance aiming at a VDAC1 target spot in preparation of a product and a medicine for preventing and treating diseases caused by RSV, and relates to the technical field of respiratory syncytial virus resistance. A novel RSV cell receptor VDAC1 (voltage-dependent anion channel 1) independent of NCL (nucleolin) is discovered, a novel RSV infected cell receptor is identified, and discovery of the receptor provides a molecular basis for development of novel antiviral drugs and is crucial for development of novel drugs. The substance aiming at the VDAC1 target spot, provided by the invention, has a good application prospect in prevention and treatment of diseases caused by RSV, and the resistance of a subject to RSV infection can be greatly improved.